Key points – clinical practice – Leukaemia Care e-learning

Treatment-free remission (TFR) can be considered for patients who achieve deep molecular remission (at least MR⁴) with first- or second-generation tyrosine kinase inhibitors (TKIs).
The risks and benefits must be discussed thoroughly with patients before starting TFR, and patients must agree to regular monitoring to identify early molecular relapse and thereby avoid a full haematological relapse.
Some patients experience joint pains after stopping TKI treatment.
Patients with atypical CML or a history of TKI resistance, and children, are not eligible for TFR.
Dose reduction or a deliberate treatment holiday can be considered for patients who are not eligible for TFR.